Hypertension at 34 – 37 weeks: immediate delivery or wait?
Women between 34 0/7 through 36 6/7 gestational weeks with non-severe hypertensive disorders such as (1) gestational hypertension, (2) pre-eclampsia, (3) deteriorating pre-existing hypertension or superimposed pre-eclampsia were studied to determine if they should be delivered immediately or followed with close monitoring. The results of the study showed:
There was no statistical risk reduction in adverse maternal outcomes in women who were delivered immediately (1.1%) compared to expectant management (3.1%)
Maternal adverse events overall, such as thromboembolic disease, pulmonary edema and eclampsia, were relatively uncommon
There was an increase in neonatal respiratory distress syndrome in the immediate delivery group (5.7%) compared to the expectant management group (1.7%) that was statistically significant (P=0.005) which required treatment with continuous positive airway pressure and/or surfactant
Based on these findings, routine immediate delivery does not appear justified and expectant monitoring through 36 5/7 gestational weeks should be considered
In a multi-centered randomized controlled trial published in the Lancet (2015), investigators sought to determine the risks/benefits of immediate delivery compared to expectant monitoring in pregnancies between 34 and 37 weeks gestational age, following their initial study that demonstrated induction of labor compared to expectant monitoring after 37 0/7 weeks gestational age did reduce maternal harms but did not affect neonatal outcomes nor increase cesarean section rates (Lancet, 2009).
Hypertensive disorders in pregnancy are common and can occur in up to 10% of all pregnancies
In the case of non-severe hypertensive disorders, there does not appear to be sufficient benefit to delivery before 37 weeks gestation while there is risk of respiratory distress syndrome to the newborn
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan